Louis G. Lange
CIK: 0001238401
Louis G. Lange's purchase track record
Louis G. Lange has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/13/2024 | NAMS | $95K | +2.5% | -13.9% | +9.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NAMS | ▼ Sell | Open Market | 44,173 | $1.3M | 3/11/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 446 | $14K | 3/11/2026 | View on chart |
| NAMS | ▼ Sell | Other | 44,619 | $513K | 3/9/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 28,186 | $829K | 3/6/2026 | View on chart |
| NAMS | ▲ Buy | Grant | 3,400 | — | 1/7/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 68 | $0 | 6/1/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 69 | $0 | 5/1/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 69 | $0 | 4/14/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 3,102 | $0 | 3/26/2025 | View on chart |
| NAMS | ▲ Buy | Grant | 6,960 | — | 1/7/2025 | View on chart |
| NAMS | ▲ Buy | Open Market | 5,000 | $95K | 2/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RBC Capital Lowers Target to $42 for NAMS
RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.
RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.